Literature DB >> 2720863

Reactivity and toxicity of atracurium and its metabolites in vitro.

V Nigrovic1, J B Pandya, J E Klaunig, K Fry.   

Abstract

Cytotoxicity of atracurium and of its metabolites was tested in vitro. Exposure of isolated rat hepatocytes to atracurium produced cellular damage evidenced by extrusion of an intracellular enzyme, lactate dehydrogenase (LDH), into the incubation medium. Leakage of LDH was directly related to the concentration of atracurium in the medium (250 to 800 microM). If the spontaneous degradation of atracurium (presumably via Hofmann elimination) was first carried out in vitro and the degradation products subsequently added to the isolated hepatocytes, the leakage of LDH was also dose-dependent but larger than that observed after the addition of the parent drug. When l-cysteine was admixed to the products of the spontaneous degradation of atracurium prior to their addition to the liver cells, no leakage of LDH was observed. The results are compatible with the working hypothesis that atracurium itself and, even more so, acrylates formed in Hofmann elimination of atracurium, are reactive toward nucleophiles and damage the cells by alkylating nucleophiles present in cellular membranes. Antecedent covalent binding of acrylates to the nucleophile cysteine, i.e., the formation of acrylate-cysteine adducts, saturated the reactive capacity of acrylates for nucleophiles and thus prevented the reactive metabolites from alkylating the endogenous nucleophiles. Possible clinical consequences resulting from in vivo generation of reactive metabolites are not clear at the present time but are projected to be related to (a) the dose of atracurium administered, (b) the amount of acrylates generated, (c) the functional importance of the endogenous nucleophiles alkylated, and (d) the pathway and the speed of detoxification of atracurium and its metabolites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720863     DOI: 10.1007/BF03010762

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  17 in total

1.  The pharmacological properties of "laudolissin" a long-acting curarizing agent.

Authors:  H O J COLLIER; B MACAULEY
Journal:  Br J Pharmacol Chemother       Date:  1952-09

2.  Generation of reactive metabolites during spontaneous degradation of atracurium in vitro.

Authors:  V Nigrovic; W Gallup; J Pandya; K Fry
Journal:  Am J Med Sci       Date:  1989-01       Impact factor: 2.378

3.  Hepatotoxicity studies with primary cultures of rat liver cells.

Authors:  D C Anuforo; D Acosta; R V Smith
Journal:  In Vitro       Date:  1978-12

4.  Isolation and culture of liver cells and their use in the biochemical research of xenobiotics.

Authors:  E M Suolinna
Journal:  Med Biol       Date:  1982-10

5.  Mechanisms of cell injury in the killing of cultured hepatocytes by bromobenzene.

Authors:  A Casini; M Giorli; R J Hyland; A Serroni; D Gilfor; J L Farber
Journal:  J Biol Chem       Date:  1982-06-25       Impact factor: 5.157

6.  Comparative toxicity of atracurium and metocurine in isolated rat hepatocytes.

Authors:  V Nigrovic; J E Klaunig; S L Smith; N E Schultz; A Wajskol
Journal:  Anesth Analg       Date:  1986-11       Impact factor: 5.108

7.  Involvement of nucleophiles in the inactivation of atracurium.

Authors:  V Nigrovic; S Smith
Journal:  Br J Anaesth       Date:  1987-05       Impact factor: 9.166

8.  Mouse liver cell culture. I. Hepatocyte isolation.

Authors:  J E Klaunig; P J Goldblatt; D E Hinton; M M Lipsky; J Chacko; B F Trump
Journal:  In Vitro       Date:  1981-10

9.  The metabolism of halothane by hepatocytes: a comparison between free radical spin trapping and lipid peroxidation in relation to cell damage.

Authors:  A Tomasi; S Billing; A Garner; T F Slater; E Albano
Journal:  Chem Biol Interact       Date:  1983-09-15       Impact factor: 5.192

10.  Potentiation of atracurium toxicity in isolated rat hepatocytes by inhibition of its hydrolytic degradation pathway.

Authors:  V Nigrovic; J E Klaunig; S L Smith; N E Schultz
Journal:  Anesth Analg       Date:  1987-06       Impact factor: 5.108

View more
  5 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Atracurium, pharmacokinetics and metabolites.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

3.  Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.

Authors:  R H Vandenbrom; J M Wierda; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 4.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 5.  Which drug--steroid or benzylisoquinolinium?

Authors:  B J Pollard
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.